メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
岡山大学 ホーム
English
日本語
岡山大学でコンテンツを検索
ホーム
プロファイル
研究部門
研究成果
設備
活動
プレス/メディア
受賞
Scopus著者プロファイル
友昭 山野井
助教
,
岡山大学病院
h-index
56
被引用数
4
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2017
2026
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(21)
類似のプロファイル
(6)
フィンガープリント
tomoaki yamanoiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Metastatic Renal Cell Carcinoma (mRCC)
75%
Immune Checkpoint Inhibitors
65%
Renal Cell Carcinoma
50%
Tyrosine Kinase Inhibitor
38%
First-line Therapy
30%
Treatment-related Adverse Events
28%
Clinical Outcomes
28%
Neutrophils
27%
Percutaneous Cryoablation
25%
Partial Images
25%
Matched Comparison
25%
Image-guided
25%
Propensity Score Analysis
25%
Robot-assisted Partial Nephrectomy
25%
Efficacy Comparison
25%
Propensity Score Matching
25%
Baseline Tumor Size
25%
Cefditoren pivoxil
25%
Advanced Renal Cell Carcinoma
25%
Body Mass Index
25%
Low Body Mass Index
25%
High Body Mass Index
25%
Retrospective Cost Analysis
25%
Predictive Marker
25%
Upper Urinary Tract Carcinoma
25%
Factor Analysis
25%
Carcinoma in Situ
25%
Factors Predicting
25%
Downstaging
25%
Kidney Transplant Recipients
25%
Diagnostic Ureteroscopy
25%
Immune Checkpoint Inhibitor Combination Therapy
25%
Ureteroscopy
25%
Tacrolimus
25%
KRT7
25%
Eosinophils
25%
Malignant Neoplasms
25%
National Health Insurance Research Database (NHIRD)
25%
Cell Analysis
25%
Retrospective Cohort Study
25%
PTGDS
25%
Bladder Management
25%
Toddlerhood
25%
Bedwetting
25%
Energy Therapies
25%
Renal Ischemia-reperfusion Injury
25%
Metabolic
25%
Adenosine
25%
Dapagliflozin
25%
Real-time Imaging
25%
Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
100%
Kidney Metastasis
36%
Immune Checkpoint Inhibitor
35%
Combination Therapy
34%
Malignant Neoplasm
29%
Neoplasm
27%
Transitional Cell Carcinoma
27%
Bladder
27%
Neutrophil
27%
Metastatic Carcinoma
26%
Kidney Autotransplantation
25%
Pembrolizumab
25%
Body Mass Index
25%
Cost Benefit Analysis
25%
Cryoablation
25%
Partial Nephrectomy
25%
Carcinoma in Situ
25%
Urinary Tract Carcinoma
25%
Ureteroscopy
25%
Adverse Event
25%
Predictive Marker
25%
Clear Cell Carcinoma
25%
Retrospective Cohort Study
25%
Kidney Graft
25%
Upper Urinary Tract
25%
Eosinophil
25%
Tacrolimus
25%
Quantitative Proteomics
25%
Cohort Analysis
25%
Nocturnal Enuresis
25%
Kidney Ischemia
25%
Prostate Hypertrophy
25%
Hematuria
25%
Dapagliflozin
25%
Adenosine
25%
Reperfusion Injury
25%
Antithrombotic Therapy
25%
Computer Assisted Tomography
20%
Health Care Cost
19%
Stereotactic Body Radiation Therapy
15%
Systemic Therapy
15%
Odds Ratio
11%
Antithrombotic
11%
Recurrent Disease
10%
Urinary Tract
10%
Multivariate Analysis
9%
Cyclosporine
9%
Kidney Transplantation
8%
Primary Tumor
8%
Surgery
8%
Pharmacology, Toxicology and Pharmaceutical Science
Kidney Metastasis
97%
Immune Checkpoint Inhibitor
84%
Pembrolizumab
50%
Transitional Cell Carcinoma
50%
Renal Cell Carcinoma
50%
Protein Tyrosine Kinase Inhibitor
38%
Overall Survival
36%
Progression Free Survival
34%
Combination Therapy
34%
Ipilimumab
28%
Nivolumab
28%
Adverse Event
28%
Malignant Neoplasm
26%
Immunotherapy
26%
Neoplasm
25%
Antacid Agent
25%
Proton Pump Inhibitor
25%
Cefditoren Pivoxil
25%
Tacrolimus
25%
Desensitization
25%
Prevalence
25%
Urinary Tract Infection
25%
Cohort Study
25%
Kidney Ischemia
25%
Dapagliflozin
25%
Reperfusion Injury
25%
Adenosine
25%
Liver Metastasis
20%
Histamine H2 Receptor Antagonist
17%
Primary Tumor
11%
Clinical Trial
10%
Ciclosporin
9%
Tumor Microenvironment
8%
Metastasis
8%
Disease
8%
Recurrent Disease
8%
Cancer Specific Survival
7%
Heart Muscle Ischemia
7%
sodium glucose cotransporter-2 inhibitors
7%
Acute Kidney Failure
7%
Gelatinase B
7%
Receptor Antagonist
7%
Acute Graft Rejection
5%
